ALBANY, N.Y.--(BUSINESS WIRE)--July 24, 2006--Albany Molecular Research, Inc. (Nasdaq: AMRI - News) today announced a multi-year drug substance manufacturing agreement with New River Pharmaceuticals Inc. (Nasdaq: NRPH - News). Financial terms were not disclosed. Under the agreement, AMRI will manufacture the active pharmaceutical ingredient in New River’s compound, NRP104, a new treatment for attention deficit hyperactivity disorder (ADHD) that is currently under review with the U.S. Food and Drug Administration. AMRI participated with New River in the development of the chemical process to manufacture NRP104.
